RxDoctor Payments Data

Hilary Ugras

Nurse Practitioner · Boston, MANPI 1083099840

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Sanofi at 57.3% of the total. 2025 is the largest year on record at $13,158, more than ten times the $522 reported in 2022. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,761in general payments, 2019–2025

Across 37 payments — averaging $507.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Regeneron$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Phathom Pharmaceuticals, Inc.$478
  • Ardelyx, Inc.$450
  • plus $137 from 2 others

What the payments were for

  • Consulting fees$6,13533%
  • Speaking & faculty fees$10,21954%
  • Travel & lodging$1,1736%
  • Food & beverage$1,2347%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,761 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$24,560
Medicare patients
156
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab15$141,408
LinzessLinaclotide56$54,767
MotegrityPrucalopride Succinate23$20,025
VoqueznaVonoprazan Fumarate13$8,380
MovantikNaloxegol Oxalate14$5,614
Lubiprostone11$3,688
Esomeprazole Magnesium36$1,807
Omeprazole47$910
Pantoprazole Sodium15$330
Famotidine22$319
Nortriptyline Hcl13$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,084$20,02523 claims
Phathom Pharmaceuticals, Inc.Voquezna$478$8,38013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →